



Standard Guide for Identification of Bacteriophage M13 or Its DNA¹

This standard is issued under the fixed designation E1493; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ϵ) indicates an editorial change since the last revision or reapproval.

INTRODUCTION

This guide covers the identification of bacteriophage M13 or its DNA and was developed by Task Group E48.02.03 on viruses. The objective is to describe laboratory characterization procedures that would be sufficient to verify that a biological preparation believed to contain M13 (or M13 DNA) for use in any step of a biotechnology process actually does contain this bacteriophage (or its DNA).

This guide assumes a basic knowledge of microbiology and molecular biology.

1. Scope

1.1 This guide covers the identification of bacteriophage M13 used in biotechnology.

1.2 There are many variants of M13 that have been developed specifically for cloning technology. These variants have foreign DNA inserted into the M13 genome, causing the M13 to differ in size and genotype.

1.3 If the M13 is to be used to construct a recombinant molecule, then the criteria described in Section 6 should be used to characterize the newly made DNA.

2. Terminology

2.1 Definitions:

2.1.1 *alpha complementation*—the ability of a short amino-terminal fragment (alpha fragment) of β -galactosidase to form a functional complex with the carboxyl terminal fragment (omega fragment).

2.1.2 *F¹*—an F factor that contains a portion of the *E. coli* genome.

2.1.3 *F⁺ factor*—an episome of *E. coli*. Encoded on it are the functions necessary to produce an F pilus.

2.1.4 *F pilus*—a protrusion on *E. coli* that is necessary for mating. The F pilus also contains the receptor for phage M13.

2.1.5 *Hfr*—a strain of *E. coli* in which the F⁺ factor is inserted into the chromosome.

2.1.6 *multiple cloning site*—DNA that contains several contiguous restriction enzyme recognition sites; also called a polylinker.

¹ This guide is under the jurisdiction of ASTM Committee E55 on Manufacture of Pharmaceutical Products and is the direct responsibility of Subcommittee E55.04 on General Biopharmaceutical Standards.

Current edition approved Nov. 1, 2006. Published November 2006. Originally approved in 1992. Last previous edition approved in 2001 as E1498–01. DOI: 10.1520/E1493-06.

2.1.7 *phage display*—the use of bacteriophage M13 or a variant to insert a peptide sequence fused to a coat protein of M13.

3. Significance and Use

3.1 This guide is intended for use in a biotechnology laboratory when the need arises to identify a preparation containing M13 bacteriophage or DNA.

4. Background Information about M13 Bacteriophage

4.1 M13 is a filamentous bacteriophage that infects male (F⁺, F¹ or Hfr) *Escherichia coli*. The phage particles contain circular single-stranded DNA, 6407 nucleotides in length, coated with the protein product of the M13 gene 8. (1)²

4.2 The phage attaches to a receptor at the end of the F pilus. The infecting single-stranded DNA (+ strand) replicates in the cell: a complementary (–) strand is synthesized, resulting in a double-stranded, replicative form (RF). Using the RF as a template, both strands can be replicated, increasing the copy number of the RF to about 20 to 40 per cell. Late in infection (+) strands are preferentially produced and packaged into phage particles for export from the cell. (1)

4.3 M13 infection and subsequent phage release is not lethal to *Escherichia coli*. Bacteriophage DNA is continually replicated and packaged, causing a decrease in the growth rate of the host. The “plaque” seen upon infection by M13 is the result of an area of decreased growth rate, not actually cell killing. (1)

4.4 M13 has extensive sequence homology to bacteriophages f1 and fd, differing in only a few bases. (1)

4.5 M13 is used in biotechnology often as a vector into which foreign DNA can be cloned. Commonly used M13

² The boldface numbers in parentheses refer to a list of references at the end of this standard.

variants are the M13 mp series. These M13 bacteriophages have a portion of the *E. coli lac* operon with a multiple cloning site within a truncated *lacZ* gene.

4.5.1 A portion of the *E. coli lac* operon containing the 3-prime end of the *lacI* gene, the *lac* promoter and operator, and the alpha complementation portion of the *lacZ* gene is inserted near the origin of replication of the M13. **(2, 3, 4)**

4.6 M13 or variants are used in phage display for the selection of proteins or peptides with improved or novel binding characteristics. Typically, a DNA library containing the potential coding sequences for the peptides is cloned into one of the genes for the M13 coat proteins resulting in a fusion between the coat protein and the peptide. The phage produced are test-bound to a matrix containing the binding site; the phage which bind are enriched for, and the remainder discarded. Often, several rounds of this selection are preformed. **(5, 6, 7)**

5. Bacteriophage Growth and Purification

5.1 Bacteriophage M13 can be grown by any of a number of published protocols. **(3, 4)**

5.2 Depending upon whether single-stranded (+) strand DNA in phage particles or RF DNA is desired, different protocols would be used.

5.2.1 The (+) strand DNA is exported as phage particles from cells infected with M13 phage. Cells from a single plaque are grown with vigorous aeration for 5 to 8 h. Longer times will result in fewer phage particles. The bacterial cells are centrifuged out and the bacteriophage remain in the superna-

tant fraction. The phage particles are usually precipitated and concentrated using polyethylene glycol. If the DNA is desired, the protein coat is disrupted using phenol.

5.2.2 Double-stranded RF DNA is isolated from cells that have been grown overnight. RF DNA can be isolated using a protocol for plasmid DNA purification.

6. Characterization Criteria

6.1 Bacteriophage M13 has various different uses however, the characterization of double-stranded RF DNA by restriction enzyme analysis or of the single-stranded phage DNA by DNA sequencing should be the criterion for determination.

6.1.1 RF DNA analysis using restriction enzymes shall be accomplished using any one of a number of protocols. **(3, 4)**

6.1.2 Sequencing the single-stranded virion DNA can be accomplished using the Sanger dideoxy chain termination method. **(3, 4)**

6.1.3 There are a number of variants of M13 that have been genetically engineered for use as cloning and phage display vectors. These variants differ from one another usually in orientation and content of the multiple cloning site. One variant can be distinguished from another by either restriction enzyme analysis of the RF DNA or DNA sequencing. Sequencing the multiple cloning site region is sufficient for discrimination among the variants.

7. Keywords

7.1 bacteriophage; cloning vector; DNA sequencing; M13; phage display; recombinant DNA

REFERENCES

- (1)** Rasched, I., and Oberer, E., "Ff coliphages, Structural and Functional Relationships," *Microbiological Reviews*, Vol 50, 1986, pp. 401–427.
- (2)** Messing, J., "Cloning in M13 Phage or How to Use Biology At Its Best," *Gene*, Vol 100, 1991, pp. 3–12.
- (3)** Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Smith, J.A., Seidman, J.G., and Struhl, K., eds., *Current Protocols in Molecular Biology*, Greene Publishing Associates and Wiley-Interscience, New York, NY, 1989.
- (4)** Sambrook, J., Fritsch, E.F., and Maniatis, T., *Molecular Cloning, A Laboratory Manual*, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
- (5)** Dunn, I.S., "Phage Display of Proteins," *Current Opinion in Biotechnology*, Vol 5, 1996, pp. 547–553.
- (6)** Griffiths, A.D., and Duncan, A.R., "Strategies for Selection of Antibodies by Phage Display," *Current Opinion in Biotechnology*, Vol 9, 1998, pp. 102–108.
- (7)** Forrer, P., Jung, S., and Pluckthun, A., "Beyond binding: using phage display to select for structure, folding and enzymatic activity in proteins," *Current Opinion in Structural Biology*, Vol 9, 1999, pp. 514–520.

ASTM International takes no position respecting the validity of any patent rights asserted in connection with any item mentioned in this standard. Users of this standard are expressly advised that determination of the validity of any such patent rights, and the risk of infringement of such rights, are entirely their own responsibility.

This standard is subject to revision at any time by the responsible technical committee and must be reviewed every five years and if not revised, either reapproved or withdrawn. Your comments are invited either for revision of this standard or for additional standards and should be addressed to ASTM International Headquarters. Your comments will receive careful consideration at a meeting of the responsible technical committee, which you may attend. If you feel that your comments have not received a fair hearing you should make your views known to the ASTM Committee on Standards, at the address shown below.

This standard is copyrighted by ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959, United States. Individual reprints (single or multiple copies) of this standard may be obtained by contacting ASTM at the above address or at 610-832-9585 (phone), 610-832-9555 (fax), or service@astm.org (e-mail); or through the ASTM website (www.astm.org). Permission rights to photocopy the standard may also be secured from the ASTM website (www.astm.org/COPYRIGHT).